No Data
Kexing Biopharm Gets Clinical Trial Approval for GB18 Injection
Kexing Biopharm (688136.SH): Clinical trial registration application for GB18 injection received acceptance.
On March 21, Gelonghui reported that Kexing Biopharm (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (referred to as "Shenzhen Kexing"), received the administrative licensing document from the National Medical Products Administration titled "Acceptance Notice." The clinical trial application for the "GB18 injection" submitted by Shenzhen Kexing has been accepted. GB18 is an innovative drug targeting GDF15 (Growth Differentiation Factor 15), specifically designed for the treatment of cancer cachexia. This molecule features a unique Fc fusion nanoantibody structural design, which not only improves the drug's stability and bioavailability but also significantly enhances its inhibition.
Even With A 26% Surge, Cautious Investors Are Not Rewarding Kexing Biopharm Co., Ltd.'s (SHSE:688136) Performance Completely
Kexing Biopharm to Undertake Up to 60 Million-Yuan Share Buyback
Kexing Biopharm Co., Ltd. (SHSE:688136) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Kexing Biopharm (688136.SH) plans to spend 30 million to 60 million yuan to repurchase shares.
Kexing Biopharm (688136.SH) has announced a share repurchase plan, with the total amount for this repurchase not exceeding 6 million yuan...
Revenues Working Against Shandong Kexing Bioproducts Co,.Ltd's (SHSE:688136) Share Price Following 26% Dive